ACXP vs. LLY

Last updated Jun 23, 2026

ACXP (Acurx Pharmaceuticals, Inc.) and LLY (Eli Lilly and Company) are both stocks. Both are in the Healthcare sector — ACXP in Biotechnology, LLY in Drug Manufacturers - General. Over the past 3 years, ACXP returned -69.14%/yr vs 35.08%/yr for LLY. At a 0.05 correlation, their price movements are largely independent.

Performance

ACXP vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Acurx Pharmaceuticals, Inc. (ACXP) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ACXP achieves a -39.36% return, which is significantly lower than LLY's 3.36% return.

ACXP

• 1D: -1.95%
• 1M: -23.35%
• YTD: -39.36%
• 6M: -56.23%
• 1Y: -86.27%
• 3Y*: -69.14%
• 5Y*: —
• 10Y*: —

LLY

• 1D: 0.45%
• 1M: 3.95%
• YTD: 3.36%
• 6M: 3.66%
• 1Y: 44.67%
• 3Y*: 35.08%
• 5Y*: 37.87%
• 10Y*: 33.14%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ACXP vs. LLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
ACXP Acurx Pharmaceuticals, Inc.	-39.36%	-84.71%	-78.75%	-3.77%	-7.90%	-27.37%
LLY Eli Lilly and Company	3.36%	40.25%	33.30%	60.91%	34.26%	19.33%

Correlation

The correlation between ACXP and LLY is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.11
Correlation (3Y) Calculated over the trailing 3-year period	0.11
Correlation (All Time) Calculated using the full available price history since Jun 25, 2021	0.05

Fundamentals

Market Cap ACXP : $4.10M LLY : $991.83B
EPS ACXP : -$959.29 LLY : $28.14
PB Ratio ACXP : 0.00 LLY : 31.79
Total Revenue (TTM) ACXP : $0.00 LLY : $72.25B
Gross Profit (TTM) ACXP : $0.00 LLY : $59.75B
EBITDA (TTM) ACXP : -$5.88M LLY : $32.97B

Return for Risk

ACXP vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACXP

ACXP Risk / Return Rank: 14
ACXP Sharpe Ratio Rank: 22
ACXP Sortino Ratio Rank: 15
ACXP Omega Ratio Rank: 17
ACXP Calmar Ratio Rank: 3
ACXP Martin Ratio Rank: 13

LLY

LLY Risk / Return Rank: 74
LLY Sharpe Ratio Rank: 77
LLY Sortino Ratio Rank: 72
LLY Omega Ratio Rank: 73
LLY Calmar Ratio Rank: 75
LLY Martin Ratio Rank: 76

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACXP vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Acurx Pharmaceuticals, Inc. (ACXP) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ACXP	LLY	Difference
Sharpe ratio: Return per unit of total volatility	-0.46	1.19	-1.65
Sortino ratio: Return per unit of downside risk	-0.83	1.75	-2.58
Omega ratio: Gain probability vs. loss probability	0.91	1.24	-0.32
Calmar ratio: Return relative to maximum drawdown	-0.97	1.94	-2.90
Martin ratio: Return relative to average drawdown	-1.25	4.84	-6.08

ACXP vs. LLY - Sharpe Ratio Comparison

The current ACXP Sharpe Ratio is -0.46, which is lower than the LLY Sharpe Ratio of 1.19. The chart below compares the historical Sharpe Ratios of ACXP and LLY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

ACXP vs. LLY - Drawdown Comparison

The maximum ACXP drawdown since its inception was -99.14%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for ACXP and LLY.

Drawdown Indicators

	ACXP	LLY	Difference
Max Drawdown Largest peak-to-trough decline	-99.14%	-68.24%	-30.90%
Max Drawdown (1Y) Largest decline over 1 year	-89.26%	-23.18%	-66.08%
Max Drawdown (3Y) Largest decline over 3 years	-98.83%	-34.48%	-64.35%
Max Drawdown (5Y) Largest decline over 5 years	—	-34.48%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-34.48%	—
Current Drawdown Current decline from peak	-99.04%	-4.64%	-94.40%
Average Drawdown Average peak-to-trough decline	-69.51%	-19.20%	-50.31%
Ulcer Index Depth and duration of drawdowns from previous peaks	69.15%	9.26%	+59.89%

Volatility

ACXP vs. LLY - Volatility Comparison

Acurx Pharmaceuticals, Inc. (ACXP) has a higher volatility of 12.17% compared to Eli Lilly and Company (LLY) at 8.54%. This indicates that ACXP's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ACXP	LLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.17%	8.54%	+3.63%
Volatility (6M) Calculated over the trailing 6-month period	119.74%	26.85%	+92.89%
Volatility (1Y) Calculated over the trailing 1-year period	188.57%	37.83%	+150.74%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	140.92%	32.45%	+108.47%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	140.92%	30.20%	+110.72%

Dividends

ACXP vs. LLY - Dividend Comparison

ACXP has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.58%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ACXP Acurx Pharmaceuticals, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.58%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%

Financials

Frequently Asked Questions

Can I hold both ACXP and LLY in my portfolio?

ACXP and LLY have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ACXP or LLY?

ACXP has higher volatility (12.17%) compared to LLY (8.54%). In terms of maximum drawdown, ACXP dropped -99.14% vs LLY's -68.24%.

Which has better risk-adjusted returns?

LLY currently has the higher Sharpe Ratio (1.19 vs -0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.